 Insulin, a new culture medium engineered to enhance protein expression in insulin-dependent CHO cell lines, which are widely used in the production of monoclonal antibodies, biosimilars, and other protein therapeutics.){kind=link}
Thermo Fisher Scientific, has introduced Gibco™ Efficient-Pro™ Medium (+) Insulin, a new culture medium engineered to enhance protein expression in insulin-dependent CHO cell lines, which are widely used in the production of monoclonal antibodies, biosimilars, and other protein therapeutics. The formulation builds on the company’s existing Efficient-Pro medium and feed system, integrating insulin supplementation to improve reproducibility, simplify workflows, and reduce process variability.
According to Thermo Fisher, comparative studies indicate that Efficient-Pro Medium (+) Insulin can deliver up to 61% higher protein titers relative to alternative media, without compromising product quality. Reported attributes include:
- High viable cell densities with robust growth performance across multiple insulin-dependent CHO lineages.
- Compatibility with a variety of packaging and formulation formats, including Advanced Granulation Technology™ (AGT™) dry media, which allows rapid reconstitution and scalability.
- An animal origin–free composition aimed at reducing regulatory complexity and improving batch-to-batch consistency.
Insulin supplementation has long been a critical component for sustaining the growth and productivity of many CHO-based systems. By embedding insulin in a standardized, ready-to-use format, Thermo Fisher is positioning Efficient-Pro Medium (+) Insulin as a solution for biopharmaceutical manufacturers, biotechnology companies, and CDMOs seeking both higher yield and simplified process development.
In particular, the medium is targeted at developers of monoclonal antibodies, bispecifics, Fc-fusion proteins, and other complex biologics, where consistency, scalability, and regulatory assurance remain central challenges.
Our announcement represents a significant enhancement in bioprocessing technology. By integrating our AGT format and ensuring an AOF formulation, we are addressing key industry challenges and providing our customers with a reliable, high-performance solution. Efficient-Pro Medium (+) Insulin underscores our dedication to innovation and our mission to support the development of groundbreaking therapies that improve patient outcomes worldwide.
Sara Henneman, Vice President and General Manager of Thermo Fisher Scientific’s Cell Culture and Cell Therapy business unit